321 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author이동윤-
dc.date.accessioned2021-03-31T00:43:33Z-
dc.date.available2021-03-31T00:43:33Z-
dc.date.issued2020-01-
dc.identifier.citationBIOINSPIRED BIOMATERIALS: ADVANCES IN TISSUE ENGINEERING AND REGENERATIVE MEDICINE, v. 1249, page. 203-221en_US
dc.identifier.isbn978-981-15-3258-0-
dc.identifier.isbn978-981-15-3257-3-
dc.identifier.issn0065-2598-
dc.identifier.issn2214-8019-
dc.identifier.urihttps://link.springer.com/chapter/10.1007%2F978-981-15-3258-0_13-
dc.identifier.urihttps://repository.hanyang.ac.kr/handle/20.500.11754/160978-
dc.description.abstractDespite the use of active surgeries, radiotherapy, and chemotherapy in clinical practice, brain tumors are still a difficult health problem due to their rapid development and poor prognosis. To treat brain tumors, various nanoparticles can be used to target effective physiological conditions based on continuously changing vascular characteristics and microenvironments to promote effective brain tumor-targeting drug delivery. In addition, a brain tumor-targeting drug delivery system that increases drug accumulation in the brain tumor area and reduces toxicity in the normal brain and peripheral tissues is needed. However, the blood-brain barrier is a big obstacle for drug delivery to the brain. In this chapter, we provide a broad overview of brain drug delivery and current strategies over the last few years. In addition, several questions have been reconsidered, such as whether nanoparticles believed to be delivered to the brain can pass through the blood-brain barrier, whether the drug is delivered to the target site, and what brain tumor treatment is possible.en_US
dc.description.sponsorshipThis study was supported by the Bio & Medical Technology Development Program (NRF-2015M3A9E2030125) and was partially supported by the Creative Materials Discovery Program (NRF-2017M3D1A1039289) through the National Research Foundation (NRF) funded by the Korean government (MSIP & MOHW). Also, this study was partially supported by a grant of the Korea Health Technology R&D project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI18C0453).en_US
dc.language.isoenen_US
dc.publisherSPRINGER-VERLAG SINGAPORE PTE LTDen_US
dc.subjectBrain tumoren_US
dc.subjectDrug deliveryen_US
dc.subjectOral administration of protein-based drugen_US
dc.subjectDrug stabilityen_US
dc.titleProtein-based drug delivery in brain tumor therapyen_US
dc.typeArticleen_US
dc.relation.volume1249-
dc.identifier.doi10.1007/978-981-15-3258-0_13-
dc.relation.page203-221-
dc.relation.journalADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY-
dc.contributor.googleauthorHwang, Hae Hyun-
dc.contributor.googleauthorLee, Dong Yun-
dc.relation.code2020045429-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF ENGINEERING[S]-
dc.sector.departmentDEPARTMENT OF BIOENGINEERING-
dc.identifier.piddongyunlee-
Appears in Collections:
COLLEGE OF ENGINEERING[S](공과대학) > BIOENGINEERING(생명공학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE